The Research

The development of Panakeia was made possible by blocking some of the passageways of the biosynthetic route of cannabinoids, thus preventing the formation of THC, the psychoactive component, and increasing the accumulation of CBG, a cannabinoid that until now was only found in vestigial amounts in the plant.

That means a double achievement: not only has THC been eliminated, but the concentration of CBG has been increased.

This research was conducted by the Polytechnic University of Valencia (UPV, whom we have been working with since 2013), one of the entities in Spain which holds a license to cultivate cannabis for scientific purposes. The result is a very attractive strain specially for medicinal cannabis patients for its therapeutic properties as well as for researchers and pharmaceutical companies interested in exploiting the medicinal properties of cannabis.